Olink to provide proteomics data from 53,000 UK Biobank participants

We are proud to announce that the Olink® Explore 1536 platform, utilizing Next Generation Sequencing (NGS) as read-out, will be used in a project to measure plasma protein concentration in 53,000 individuals from the UK Biobank, one of the world’s largest genetic resources. The proj...

Longitudinal proteomic profiling of high-risk patients with COVID-19

Pre-print now available: Markers of severity and predictors of fatal disease identified in high-risk patients with COVID-19 Background/design End-stage kidney disease (ESKD) patients are at high risk of severe COVID-19, and in this study, longitudinal protein profiling with five dif...

On-demand Webinar – Longitudinal plasma proteomics of severe COVID-19

Free Olink-sponsored Science/AAAS webinar Please watch an exciting and highly topical webinar, “Investigating cellular pathways driving severe COVID-19: Fresh insights from longitudinal plasma proteomics“. – Now available as an on-demand r...

SCALLOP publication in Nature Metabolism

A study of cardiovascular proteins in over 30 000 individuals A major proteogenomic study from SCALLOP identifies >450 pQTLs and several novel potential drug targets   Illustration by Ann-Louise Bergström (Moving Science ApS) In an important new study published in Nature...

On-demand webinar – A systems-level approach to understanding the immunology of COVID-19 in adults and children

Dr. Petter Brodin Now available as an on-demand recording An Olink-sponsored SelectScience webinar, “A systems-level approach to understanding the immunology of COVID-19 in adults and children“. Original broadcast date: Wednesday October 21, 2020 at 17.0...

Plasma ACE2 and risk of death or cardiometabolic diseases

Large epidemiological study of association of plasma ACE2 levels with CVD risk Cardiovascular diseases have been one of the most studied comorbidities in connection with COVID-19. A study by researchers at Hamilton Health Sciences in Ontario, Canada has examined the levels of the S...

Update of our Target 96 Development panel (Oct 2020)

In response to customer feedback and as part of Olink’s commitment to improve and develop our offering, a change has been made to the Olink®Target 96 Development panel. A high performance assay with a possible role in bone remodeling, metabolic diseases and tumorigenesis has been selected from...

MGH/Olink collaboration to investigate the plasma proteomic signatures of COVID-19 positive patients

Olink Explore 1536 accelerates COVID-19 research and the identification of new biomarkers Olink is immensely proud of our contribution to one of the largest longitudinal COVID-19 studies to date, together with the prestigious Massachusetts General Hospital (MGH). In close collaboration with the team...

Multisystem Inflammatory Syndrome in Children with COVID-19

Insights into a rare but severe complication in children with COVID-19 A study by Petter Brodin’s group at the Karolinska Institiute has looked into an aspect of the COVID-19 pandemic that has perhaps not received enough attention to date. While the large majority of children ...

Immune response in mild versus severe COVID-19 infections

New insights into immune responses in severe COVID-19 A study by researchers at Stanford University and other institutions reveals how the immune system goes awry leading to severe disease during SARS-CoV-2 infections,  and may point to novel therapeutic targets. Taking a systems bi...